Recorded Live at ONS Congress 2019
Instructions for Credit — There is no fee for this activity. To receive credit for this CE activity, participants must enroll in this course, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.25 continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers at the intermediate and advanced levels involved in the care of patients with myeloma.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||List at least two new drugs/new applications to treat patients with myeloma, along with monitoring and managing side effects|
|•||Assess long-term and late effects of myeloma and myeloma treatments|
|•||Identify populations at high risk for myeloma|
|•||Describe barriers patients face in accessing treatment and ways to address|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses and Social Workers
Nurse Practitioner Credit Designation
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 1.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19073785. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.25 CE clinical contact hours.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.25 CE clinical contact hours for this activity.
For questions, grievances, or assistance please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Ann F. Mohrbacher, MD has disclosed she is on the Speaker’s Bureau for Takeda and Genentech.
Katrice J. Royster, MS, RN, OCN®, has no affiliations with commercial interests to disclose.
Content Expert Reviewer Disclosure
Ning Ma, NP, content expert reviewer, has nothing to disclose.
Disclaimer — The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
|Estimated time to complete activity: 1.25 hours|
|Date of initial release: May 22, 2019|
|Valid for CE credit through: May 22, 2020|
Ann F. Mohrbacher, MD, is a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.
Katrice J. Royster, MS, RN, OCN ®, has been an oncology nurse at the Marlene & Stewart Greenebaum Comprehensive Cancer Center for the past 26 years caring for inpatient hematology and medical oncology patients. Her practice focus is patient education. She leads the efforts on her unit to educate patients and their families about their diseases, treatments and side effects. She is a member of the hospital’s patient education council and is the chairperson of the Cancer Center Patient Education Committee. Under her leadership, the committee has created numerous patient and family educational handouts that are used throughout the cancer center and the hospital. She is a member of the Oncology Nursing Society and has presented posters at their annual conferences. She is an Oncology Nursing Society awards reviewer and a reviewer of poster abstracts submitted for consideration to be presented at society conferences.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
Myeloma Specific Resources: www.LLS.org/Myeloma
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources: www.LLS.org/support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with clinical trial specialists who are registered nurses with expertise in blood cancers. RNs will personally assist through the clinical trial process, providing an additional resource to your HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists